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delirious after surgery. Moreover, of the 16 patients taking 
both ramelteon and suvorexant, no postoperative delirium 
was observed. Ramelteon with or without suvorexant was 
significantly associated with a decreased rate of postop-
erative delirium compared with minor tranquilizer use 
(p = 0.001). Multivariate analysis confirmed that the use of 
ramelteon with or without suvorexant was the only signifi-
cant preventive factor of postoperative delirium (odds ratio 
0.060, p = 0.013).
Conclusion The use of ramelteon with or without suvorex-
ant was the only significant preventive factor of postopera-
tive delirium after pharyngolaryngectomy with esophagec-
tomy. However, using minor tranquilizers was associated 
with postoperative delirium. We recommend ramelteon 
with or without suvorexant for preventing postoperative 
delirium after pharyngolaryngectomy with esophagectomy.
Keywords Pharyngolaryngectomy with esophagectomy · 
Postoperative delirium · Minor tranquilizers · Ramelteon · 
Suvorexant
Introduction
Delirium is defined as a change in mental status caused by 
physical disorders, and it is characterized by disturbed con-
sciousness, reduced ability to focus, and changed cognitive 
function [1, 2]. Indeed, delirious patients are often disorien-
tated in time, place, and person. Based on clinical presenta-
tion, delirium has been classified into three motor subtypes: 
hyperactive/agitated, hypoactive/somnolent, and mixed; the 
latter of these fluctuates between the hyperactive and hypo-
active types during the course of the illness [1, 2].
Postoperative delirium is a common and serious compli-
cation after extensive surgery. However, there are important 
Abstract 
Background Postoperative delirium is common after exten-
sive surgery, and is known to be associated with sleeping 
medications. In this study, we aimed to investigate the rela-
tionships between sleeping medications and postoperative 
delirium after pharyngolaryngectomy with esophagectomy.
Methods We performed a retrospective analysis of 65 
patients who underwent pharyngolaryngectomy with 
esophagectomy at Shizuoka Cancer Center Hospital 
between January 2012 and March 2016. All data were 
assessed by two psychiatrists, and univariate and multivari-
ate analyses were performed.
Results Postoperative delirium developed in 9 (13.8%) 
patients, with most cases (77.8%) occurring between post-
operative day (POD) 1 and POD 3. Of the 24 patients tak-
ing a minor tranquilizer after surgery, 8 (33.3%) became 
delirious, but, of the remaining 41 patients taking ramelt-
eon with or without suvorexant, only one (2.4%) became 
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pre-, peri-, and postoperative factors associated with the 
risk of its development [1]. We previously reported the 
incidence and risk factors for postoperative delirium after 
major surgery for head and neck cancer [1]. In that study, 
we concluded that most cases of postoperative delirium 
occurred between postoperative day (POD) 1 and POD 
3. An associated multivariate analysis revealed that being 
older than 70 years was a significant risk factor for postop-
erative delirium [1].
Pharyngolaryngectomy with esophagectomy has been 
shown to be a highly invasive surgery, following which 
patients cannot speak because of the removal of the larynx 
[1, 3, 4]. We considered that the patients were at particularly 
high risk of developing postoperative delirium after this sur-
gery because of their inability to express feelings verbally 
[1]. Moreover, patients often complain of insomnia after 
such extensive surgery, and sleeping medications are fre-
quently needed [5]. Of the therapeutic options, it has been 
reported that minor tranquilizers promote the development of 
postoperative delirium. By contrast, ramelteon, which is an 
agonist of melatonin approved for the treatment of insomnia 
characterized by difficulty at sleep onset by the US Food and 
Drug Administration, has been associated with reduced rates 
of postoperative delirium [5, 6]. Suvorexant, which is a dual 
orexin receptor antagonist that was approved in late 2014 in 
the US and Japan for the treatment of insomnia character-
ized by difficulty achieving and/or maintaining sleep, could 
also have similar beneficial associations with postoperative 
delirium, but this has not been studied to date [7].
We hypothesized that combination therapy with ramelt-
eon and suvorexant could prevent postoperative delirium 
after pharyngolaryngectomy with esophagectomy. In this 
study, we, therefore, aimed to investigate the relationships 
between sleeping medications and postoperative delirium 
after pharyngolaryngectomy with esophagectomy.
Patients and methods
Patients
We retrospectively analyzed the records of 65 patients who 
underwent pharyngolaryngectomy with esophagectomy 
at Shizuoka Cancer Center Hospital, Shizuoka, Japan. All 
patients undergoing the procedure between January 2012 
and March 2016 were included. The study was conducted 
with the approval of the Ethics Committee of Shizuoka 
Cancer Center Hospital.
Surgical procedure
Pharyngolaryngectomy with esophagectomy was per-
formed by esophageal or head and neck surgeons based 
on tumor location. Free jejunal transfer with microvascu-
lar anastomosis was performed to repair the cervical defect 
between the hypopharynx and the oral side of the remnant 
esophagus by plastic and reconstructive surgeons in all 
cases [3]. Two anastomoses were required: pharyngojejunal 
and jejunal-esophageal.
Postoperative management
All patients were managed in the intensive care unit imme-
diately after surgery, and received mechanical ventilation 
under propofol anaesthesia. All patients were extubated on 
POD 1 and then admitted to the general surgical ward. For 
postoperative analgesia, fentanyl was provided through an 
intravenous catheter and ropivacaine hydrochloride hydrate 
was provided through an epidural catheter. Enteral nutrition 
was initiated on POD 1 via a feeding tube in all cases. All 
patients received sleeping medications via a feeding tube 
from POD 1 to discharge to postoperatively treat insomnia. 
Because delirium developed 1 week postoperatively in our 
previous study, sleeping medications were administered 
throughout the duration of the hospital stay in this study 
[1]. Sleeping medications consisted of minor tranquiliz-
ers (mainly zolpidem), ramelteon (8 mg), and suvorexant 
(20 mg). Patients received minor tranquilizers between 
January 2012 and October 2013, ramelteon only between 
November 2013 and February 2015, and ramelteon with 
suvorexant between March 2015 and March 2016. When 
we changed the sleeping medications from minor tran-
quilizers to ramelteon, some patients suffered from insom-
nia, so we added suvorexant to ramelteon. If patients com-
plained of insomnia even after taking sleeping medications, 
tetracyclic antidepressants were added via a feeding tube 
and intravenous infusion of a tranquilizer, such as haloperi-
dol, was not administered.
Data collection methods
A retrospective chart review was used to collect data. Pre-
operative data included age, gender, body mass index, 
medical illness history, psychiatric illness history, smoking 
history (>10 cigarettes daily for ≥2 years), alcohol con-
sumption (estimated weekly ethanol intake of ≥200 mL), 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, and American Society of Anesthesiologists 
physical status. Perioperative data included tumor loca-
tion, operation duration, blood loss, urinary output, amount 
of blood transfused, infusion volume, and maximum body 
temperature after surgery. Postoperative data included the 
types of sleeping medications used.
Delirium was diagnosed according to the criteria in the 
fifth edition of the Diagnostic and Statistical Manual of 
Mental Disorders, published by the American Psychiatric 
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Association [8]. All patients’ charts, which had been logged 
by surgeons, psychiatrists, and nurses, were systematically 
reviewed by two psychiatrists (T. M. and M. T.). The meth-
ods used were the same as in our previous study [1]. Data 
were collected from the day of admission to POD 14. We 
included hyperactive delirium and mixed type delirium, 
both of which were important during the postoperative 
management; however, hypoactive delirium was not so 
important during the postoperative management and was 
excluded.
Statistical analysis
The statistical analysis was performed using IBM SPSS, 
Version 23.0 (IBM Corp., Armonk, NY, USA). Demo-
graphic and surgical data (pre-, peri-, and postoperative) 
were compared between patients with and without delir-
ium. Categorical data were analyzed using Fisher’s exact 
test or the χ2 test, as appropriate. Quantitative data were 
analyzed using Mann–Whitney’s U test.
A p value of <0.05 was considered statistically signifi-
cant for all analyses, and variables that achieved signifi-
cance in the univariate analysis were entered into the mul-
tivariate analysis for estimation of the preventive factor 
of postoperative delirium. We then used multiple logistic 
regression analysis to adjust for multiple preventive factors 




The 65 study participants comprised 56 men and 9 women, 
and the median age was 66.0 (range 47–88) years. The 
demographic and perioperative data are shown for all 
patients in Tables 1 and 2. The most common tumor loca-
tion was the hypopharynx (86.2%).
Occurrence of postoperative delirium
Among the 65 patients included in the study, postopera-
tive delirium was diagnosed in 9 (13.8%), and although all 
of these cases were observed between POD 1 and POD 5, 
most (77.8%) were observed between POD 1 and POD 3 
(Fig. 1). Of the 24 patients taking minor tranquilizers after 
surgery, 8 (33.3%) developed postoperative delirium. By 
contrast, of the other 41 patients taking ramelteon with or 
without suvorexant, only 1 (2.4%) developed postoperative 
delirium after surgery; moreover, of the 16 patients taking 
both ramelteon and suvorexant, no cases of postoperative 
delirium occurred. Therapy with ramelteon with or without 
suvorexant was associated with a significantly decreased 
frequency in postoperative delirium compared with minor 
tranquilizer use (p = 0.001). Although no postoperative 
delirium occurred when suvorexant was administered with 
ramelteon, there was no significant additive effect of adding 
suvorexant to ramelteon to prevent postoperative delirium 
(p = 0.418). However, ramelteon only was not sufficient 
for insomnia, and suvorexant made up for the deficiency.
Univariate and multivariate analyses of preventive 
factors for postoperative delirium
Univariate analyses revealed that the ECOG performance 
status and the use of ramelteon with or without suvorexant 
were the preventive factors of postoperative delirium after 
pharyngolaryngectomy with esophagectomy. Using these 
as preventive factors, the subsequent multivariate logistic 
regression analysis showed that the use of ramelteon with 
or without suvorexant remained the only significant pre-
ventive factor of postoperative delirium (odds ratio 0.060) 
(Table 3). The goodness-of-fit of this model was good from 
the result of Hosmer–Lemeshow’s test (p = 0.914). The 
use of minor tranquilizers was associated with the develop-
ment of postoperative delirium.
Discussion
In a previous study by our group, postoperative delirium 
developed in 50 of 293 patients (17.1%) after surgery for 
head and neck cancer, and we did not consider the impact 
of sleeping medication on the development of postoperative 
delirium [1]. However, other research has shown that the 
use of minor tranquilizers was associated with the devel-
opment of postoperative delirium and that ramelteon might 
prevent postoperative delirium [5, 6]. In this study, we, 
therefore, investigated the association of sleeping medica-
tions with the development of postoperative delirium.
We showed that eight of the 24 patients (33.3%) tak-
ing minor tranquilizers after surgery developed postopera-
tive delirium, but that only one of the 41 patients (2.4%) 
taking ramelteon with or without suvorexant developed 
postoperative delirium. In addition, there were no cases of 
postoperative delirium among the 16 patients taking both 
ramelteon and suvorexant. These results indicate three pos-
sibilities. First, that the use of minor tranquilizers caused 
the development of postoperative delirium. Second, that 
ramelteon, suvorexant, or combination therapy with both 
drugs decreased the development of postoperative delir-
ium. Third, that both the first and second conclusions are 
correct. All patients were administered sleeping medica-
tions postoperatively and there was a lack of control group 
receiving placebo in this study, so we cannot comment on 
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the frequency of postoperative delirium in those not admin-
istered sleeping medications. However, compared with our 
previous study [1], patients taking minor tranquilizers after 
surgery did develop postoperative delirium more often, 
while those taking ramelteon with or without suvorexant 
developed postoperative delirium less often. Thus, there is 
a high possibility that the third possibility is correct, and 
that at the very least, ramelteon with or without suvorex-
ant was associated with a lower risk of producing delirium 
compared with minor tranquilizers.
Minor tranquilizers have been associated with delirium 
in most previous studies, with research showing reduced 
use after surgery and for old patients [2, 9, 10]. By con-
trast, a randomized, placebo-controlled trial has shown 
that ramelteon can help prevent delirium [6]. In vitro 
studies have also demonstrated that ramelteon has 6- and 
3-fold higher affinities for melatonin receptors 1 and 2, 
respectively, when compared with melatonin [6]. This sug-
gests that a reduced frequency of delirium might be asso-
ciated with higher affinities for these receptors, supporting 
a possible pathogenic role for melatonin neurotransmis-
sion in delirium [6]. Suvorexant is a dual orexin receptor 
antagonist that is used to treat insomnia characterized by 
difficulty achieving and/or maintaining sleep, but no report 
has been published on whether it can prevent delirium [7]. 
Nevertheless, similar to the implicated role of melatonin, 
there is a possible pathogenic role for disordered orexin 
neurotransmission in delirium.
It cannot be derived from this study whether ramelteon 
or suvorexant produced a lower risk for developing postop-
erative delirium or whether they actually prevented the con-
dition. If ramelteon and suvorexant were only associated 
with a lower risk for developing delirium, we should only 
recommend their use in patients suffering from insomnia. 
Table 1  Baseline data for 
patients with and without 
delirium
Data are shown as median (interquartile range) or number (percent)
a Alcoholism was defined as drinking an estimated weekly ethanol intake of ≥200 mL
b Chronic smoking was defined as smoking >10 cigarettes daily for at least 2 years
Variable All patients Delirium (+) Delirium (−) p value
Total 65 9 56
Age (years) 66.0 (61.5, 72.0) 69.0 (65.5, 79.0) 66.0 (61.0, 72.0) 0.128
Age category, n (%) 0.769
 <70 39 (60.0%) 5 (55.6%) 34 (60.7%)
 ≥70 26 (40.0%) 4 (44.4%) 22 (39.3%)
Gender, n (%) 0.433
 Male 56 (86.2%) 7 (77.8%) 49 (87.5%)
 Female 9 (13.8%) 2 (22.2%) 7 (12.5%)
 Body mass index (kg/m2) 19.6 (18.1, 21.6) 18.2 (16.1, 21.3) 19.9 (18.2, 21.7) 0.323
Medical history, n (%)
 Hypertension 18 (27.7%) 3 (33.3%) 15 (26.8%) 0.684
 Diabetes mellitus 10 (15.4%) 0 (0%) 10 (17.9%) 0.168
 Hyperlipidemia 2 (3.1%) 1 (11.1%) 1 (1.8%) 0.133
 Stroke 8 (12.3%) 1 (11.1%) 7 (12.5%) 0.906
 Coronary heart disease 3 (4.6%) 0 (0%) 3 (5.4%) 0.477
 Renal dysfunction 2 (3.1%) 0 (0%) 2 (3.6%) 0.565
 Malignant tumor 22 (33.8%) 2 (22.2%) 20 (35.7%) 0.427
 Psychiatric disorder 4 (6.2%) 1 (11.1%) 3 (5.4%) 0.505
 Alcoholism, n (%)a 51 (78.5%) 6 (66.7%) 45 (80.4%) 0.354
 Chronic smoking, n (%)b 58 (89.2%) 9 (100.0%) 49 (87.5%) 0.262
Performance status (Eastern Cooperative Oncology Group) 0.022
 0 37 (56.9%) 2 (22.2%) 35 (62.5%)
 1 21 (32.3%) 4 (44.4%) 17 (30.4%)
 2 7 (10.8%) 3 (33.3%) 4 (7.1%)
Physical status (American Society of Anesthesiologists) 0.798
 Grade 1 10 (15.4%) 1 (11.1%) 9 (16.1%)
 Grade 2 45 (69.2%) 6 (66.7%) 39 (69.6%)
 Grade 3 10 (15.4%) 2 (22.2%) 8 (14.3%)
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However, if ramelteon and suvorexant can actually prevent 
postoperative delirium, we should consider administering 
them to all patients at high risk of developing postopera-
tive delirium, regardless of whether or not they suffer from 
insomnia. In our previous study, an age of >70 years (odds 
ratio 3.935) was a significant determinant for postoperative 
delirium [1].
In this study, although there was no additive effect when 
suvorexant was given with ramelteon to prevent postopera-
tive delirium, it was notable that there were no cases of post-
operative delirium in any of the patients taking both medica-
tions together. Moreover, ramelteon alone was not sufficient 
to treat insomnia and suvorexant made up for the deficiency. 
It is possible that combination therapy with ramelteon and 
suvorexant had a stronger preventive effect on postopera-
tive delirium. To investigate whether ramelteon is sufficient 
alone or in combination with suvorexant to prevent postop-
erative delirium, a randomized controlled trial is needed.
There are two important limitations of our study. First, 
we used a retrospective design at a single institution, and 
it is possible that the diagnosis was not accurate. Second, 
we did not consider the length of sobriety or use of sleep-
ing medications before surgery. Nevertheless, all patients’ 
charts were systemically assessed by two psychiatrists to 
overcome some of these biases.
Table 2  Intraoperative and postoperative data in patients with and without delirium
Data are shown as median (interquartile range) or number (percent)
Variable All patients Delirium (+) Delirium (−) p value
Total 65 9 56
Tumor location, n (%) 0.873
 Oropharynx 3 (4.6%) 0 (0%) 3 (5.4%)
 Hypopharynx 56 (86.2%) 8 (88.9%) 48 (85.7%)
 Larynx 4 (6.2%) 1 (11.1%) 3 (5.4%)
 Major salivary gland 1 (1.5%) 0 (0%) 1 (1.8%)
 Thyroid 1 (1.5%) 0 (0%) 1 (1.8%)
 Operation time (min) 573.0 (522.5, 652.5) 553.0 (407.0, 696.0) 576.0 (526.0, 652.8) 0.642
 Blood loss (mL) 410.0 (289.0, 564.5) 442.0 (310.0, 776.5) 410.0 (283.5, 535.8) 0.447
 Urinary output (mL) 740.0 (482.5, 1115.0) 760.0 (447.5, 1160.0) 730.0 (492.5, 1117.5) 0.894
 Blood transfusions (mL) 0 (0, 0) 0 (0, 655.0) 0 (0, 0) 0.334
 Volume of infusion (mL) 4200.0 (3525.0, 5425.0) 3500.0 (2960.0, 6200.0) 4245.0 (3650.0, 5400.0) 0.352
 Maximum body temperature after surgery (°C) 38.1 (37.8, 38.6) 38.1 (37.7, 38.9) 38.1 (37.8, 38.5) 0.805
Sleeping medication, n (%) 0.002
 Minor tranquilizer 24 (36.9%) 8 (88.9%) 16 (28.6%)
 Ramelteon only 25 (38.5%) 1 (11.1%) 24 (42.9%)
 Ramelteon and suvorexant 16 (24.6%) 0 (0%) 16 (28.6%)
Fig. 1  Time of postoperative delirium onset
Table 3  Multivariate analysis of preventive factors for postoperative 
delirium
CI confidence interval, ECOG eastern cooperative oncology group
Variable p value Hazard ratio 95% CI
Ramelteon with or without 
suvorexant
0.013 0.060 0.0066–0.55
ECOG performance status 0.186
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In conclusion, we showed that ramelteon with or with-
out the use of suvorexant was associated with fewer cases 
of postoperative delirium after pharyngolaryngectomy with 
esophagectomy, but minor tranquilizers were associated 
with the development of postoperative delirium. We recom-
mend that treatment with ramelteon, with or without suvo-
rexant, be used instead of minor tranquilizers for patients 
undergoing pharyngolaryngectomy with esophagectomy 
after surgery to prevent postoperative delirium.
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